Agents for Drug Discovery: From Target to Molecule The pharmaceutical industry faces a productivity crisis. Developing a new drug costs an average of $2.3 billion and takes 10-15 years, with over 90% of candidates failing in clinical trials. Traditional drug discovery is a sequential, labor-intensive process: identify a target, validate it, screen millions of compounds, optimize leads, test safety, run clinical trials. Each stage can take years. Agentic AI — autonomous systems that reason, plan, and execute multi-step workflows — promises to compress this timeline dramatically. By orchestrating domain-specific models (AlphaFold for structure, ESM for protein embeddings, generative models for molecule design) with LLM reasoning, agents can automate the entire pipeline from target identification to clinical candidate selection. ...

Building Biological Tool-Use Agents: Architecture and Patterns The vision of agentic omics — autonomous AI systems that orchestrate biological discovery — depends on a deceptively simple capability: tool use. An agent that can reason about biology but cannot access BLAST, AlphaFold, or single-cell analysis pipelines is like a biologist who understands theory but has never touched a pipette. This post provides a practical architecture for building biological tool-use agents. We cover the essential tool inventory, the unique error-handling challenges of biological data, prompt engineering patterns for biological reasoning, and a reference architecture based on the ReAct (Reason + Act) loop. This is the “how-to” companion to Post 13’s conceptual overview and Post 14’s vision of agentic omics. ...

Introduction: The Convergence Point In Post 13, we defined agentic AI as systems that autonomously plan, reason, use tools, and execute multi-step scientific workflows. Now we arrive at the central thesis of this entire series: Agentic Omics — the convergence of large language model (LLM) reasoning with domain-specific biological AI models like AlphaFold, ESM, scGPT, and DNABERT to create autonomous systems capable of end-to-end biological discovery. This is not science fiction. As of early 2026, agentic systems are being deployed in operational drug discovery settings at companies like AstraZeneca, with documented implementations compressing workflows that once took months into hours while maintaining scientific traceability (Seal et al., 2025). The question is no longer if this convergence will transform biology, but how — and what architecture will get us there most reliably. ...

Introduction: Beyond the Chatbot When you ask ChatGPT a question, it answers. When you ask an agentic AI system a question, it acts. This distinction — between passive assistance and autonomous execution — marks one of the most significant shifts in artificial intelligence since the transformer architecture itself. Agentic AI systems are not merely more sophisticated chatbots. They are autonomous entities capable of perception, reasoning, planning, tool use, action, and memory. They can independently execute multi-step workflows, make decisions when faced with uncertainty, and adapt their approach based on feedback from the environment. In scientific contexts, this means agents that can read literature, formulate hypotheses, design experiments, execute computational analyses, interpret results, and iterate — all with varying degrees of human oversight. ...

Introduction: The Cellular Resolution Frontier Biology has always been a story of scale. For decades, we studied organisms, then tissues, then cell populations — averaging signals across thousands or millions of cells. But tissues are not homogeneous. A tumor contains cancer cells, immune cells, fibroblasts, and endothelial cells, each with distinct molecular profiles. The brain contains hundreds of neuronal subtypes, each with unique functions. Even “identical” cells in culture exhibit stochastic variation in gene expression that can determine cell fate. ...

Imagine two friends. One is a computational biologist, spending their days deciphering the human genome, designing complex experiments, and navigating the physical limitations of the natural world to find a cure for a rare disease. The other is a tech lead at a major software company, designing the architecture for a new feature on a widely used app. The biologist works longer hours, required a decade of post-graduate education to get their job, and arguably contributes more to the long-term survival of humanity. Yet, the software engineer earns three times their salary. Why? ...

Multi-Omics Integration: The Whole Is Greater Than the Sum Biological systems are fundamentally multi-layered. The flow of information—from DNA (genomics) to RNA (transcriptomics) to proteins (proteomics) to metabolites (metabolomics)—does not exist in isolation. Yet, for decades, bioinformatics has largely treated these “omics” layers as separate silos. Today, artificial intelligence is breaking down these walls. In this post, we explore how AI-driven multi-omics integration is transforming precision medicine and systems biology, shifting the focus from individual modalities to the interconnected entirety of the cell. ...

The Visible Layer of Biology While genomics reads the book of life and proteomics predicts the machinery that executes it, phenomics observes the actual outcome—the visible traits, cellular morphologies, and clinical presentations that emerge from the interplay of genes, environment, and chance. It is the layer we can see, measure, and often directly connect to disease. Yet phenomics has historically been the poor cousin of molecular omics. High-throughput sequencing transformed genomics and transcriptomics into data-rich disciplines, while phenotyping remained labor-intensive, subjective, and low-throughput. A pathologist examining tissue slides. A physician recording clinical observations. A biologist peering through a microscope. ...

AI for Metagenomics: Decoding the Microbiome The human microbiome is often referred to as our “second genome.” Comprising trillions of microorganisms—bacteria, archaea, fungi, and viruses—these hidden ecosystems outnumber human cells and contain vastly more genetic diversity than our own DNA. But where human genomics deals with a single species and a relatively static genome, metagenomics is the study of a dynamic, highly complex, and constantly shifting multi-species community. Decoding the microbiome is arguably one of the most data-rich and complex challenges in modern biology. Traditional bioinformatics tools, while foundational, have struggled with the compositionality, sparsity, and high dimensionality of metagenomic data. ...

Welcome back to Agentic Omics: When AI Reads the Book of Life. In our previous installments, we explored how foundation models and artificial intelligence are revolutionizing genomics, transcriptomics, and proteomics. We’ve seen how DNA, RNA, and proteins can be treated as languages, allowing transformer architectures to parse their meaning with unprecedented accuracy. Today, we turn to a different beast: Metabolomics. Metabolomics—the large-scale study of small molecules, or metabolites, within cells, biofluids, tissues, or organisms—represents the chemical phenotype of biological systems. Unlike DNA or proteins, which are linear polymers built from defined alphabets (4 nucleotides, 20 amino acids), metabolites are incredibly diverse structural entities. They do not form a neat sequence. They are the downstream products of gene expression and protein activity, intimately influenced by diet, environment, and microbiome. They are the chemical fingerprint of life at a given moment. ...